New directions in the treatment of colorectal cancer: a look to the future.

[1]  F. Maley,et al.  Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  C. Potten,et al.  The relationships between p53-dependent apoptosis, inhibition of proliferation, and 5-fluorouracil-induced histopathology in murine intestinal epithelia. , 1998, Cancer research.

[3]  Christian Jacques,et al.  Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer , 1998, The Lancet.

[4]  R. Labianca,et al.  Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer , 1998, The Lancet.

[5]  Daniel,et al.  There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. , 1998 .

[6]  J. Nemunaitis,et al.  Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  F. Lévi,et al.  Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer , 1997, The Lancet.

[8]  E. Vancutsem.  Future developments with 'Tomudex' (raltitrexed). , 1997 .

[9]  C. Potten,et al.  Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: evidence for the involvement of RNA perturbation. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[10]  C. Tournigand,et al.  Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. , 1997, European journal of cancer.

[11]  M. Yin,et al.  Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Bertino,et al.  Fluorouracil in colorectal cancer--a tale of two drugs: implications for biochemical modulation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  L. Grochow,et al.  Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  C. Potten,et al.  What is an apoptotic index measuring? A commentary. , 1996, British Journal of Cancer.

[15]  F. Lévi,et al.  Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  S. Schnitt,et al.  Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. , 1996, Journal of the National Cancer Institute.

[17]  J. Schlom,et al.  Phase I study of recombinant CEA vaccinia virus vaccine with post vaccination CEA peptide challenge. , 1996, Human gene therapy.

[18]  A. Kinsella,et al.  p53 protein overexpression and response to biomodulated 5-fluorouracil chemotherapy in patients with advanced colorectal cancer. , 1996, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[19]  D. Kerr,et al.  Gene therapy for gastrointestinal cancer , 1996 .

[20]  E. Cutsem.  A Glimpse of the Future. New Directions in the Treatment of Colorectal Cancer , 1996 .

[21]  R. Einarsson,et al.  Monitoring palliative chemotherapy in advanced gastrointestinal cancer using serial tissue polypeptide specific antigen (TPS) measurements. , 1996, Acta oncologica.

[22]  A. Watson,et al.  Apoptosis and gastrointestinal pharmacology. , 1996, Pharmacology & therapeutics.

[23]  R. Rosso,et al.  Schedule-selective biochemical modulation of 5-fluorouracil: a phase II study in advanced colorectal cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  O. Dassonville,et al.  Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  L. Påhlman,et al.  Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  O. Dassonville,et al.  [Population study of dihydropyrimidine dehydrogenase in cancer patients]. , 1994, Bulletin du cancer.

[27]  H E Rockette,et al.  The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  K. Abrams,et al.  Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases , 1994, The Lancet.

[29]  F. Lévi,et al.  Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. , 1994, Journal of the National Cancer Institute.

[30]  L. Påhlman,et al.  The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer. , 1994, British Journal of Cancer.

[31]  Y. Rustum,et al.  5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. , 1994, Cancer research.

[32]  G. Milano,et al.  A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. , 1994, European journal of cancer.

[33]  J. Bertino,et al.  Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells. , 1993, Journal of the National Cancer Institute.

[34]  C. Richards,et al.  In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. , 1993, Cancer research.

[35]  W. Scheithauer,et al.  Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. , 1993, BMJ.

[36]  B. Glimelius.  Biochemical modulation of 5-fluorouracil: a randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  P. Rougier,et al.  Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Joseph,et al.  Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. , 1992, Cancer research.

[39]  C. Louvet,et al.  High-dose folinic acid, 5-fluorouracil bolus and continuous infusion in metastatic colorectal cancer: a 3-day/3-week schedule. Group d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD) , 1992, European journal of cancer.

[40]  L. Påhlman,et al.  General condition of asymptomatic patients with advanced colorectal cancer receiving palliative chemotherapy. A longitudinal study. , 1992, Acta oncologica.

[41]  J. Hickman,et al.  Drug-target interactions: only the first step in the commitment to a programmed cell death? , 1991, British Journal of Cancer.

[42]  R. Herrmann.  Biochemical modulation of 5-fluorouracil. , 1990, Cancer treatment reviews.

[43]  Robert B. Diasio,et al.  Clinical Pharmacology of 5-Fluorouracil , 1989, Clinical pharmacokinetics.